TestEvent All Secondary Items Sold Out

Speakers

Organizers

Colin Meyer, MD

Reata Pharmaceuticals, Inc.

Dr. Meyer is the Vice President, Product Development of Reata Pharmaceuticals and joined the company as its second employee. Dr. Meyer's primary role is to develop and implement strategies to move product candidates expeditiously through all stages of development. His duties include overseeing preclinical development, clinical pharmacology, and working with Reata's senior leadership team to design and implement development strategies for drug candidates. Dr. Meyer received a B.S. in chemistry with specialization in biochemistry and a B.A. in biology from the University of Virginia. He received an M.D. from the University of Texas Southwestern Medical School and an M.B.A. from Southern Methodist University Cox School of Business.

George Zavoico, PhD

MLV

George B. Zavoico, PhD, is Managing Director, Research, and a Senior Equity Research Analyst at MLV, a boutique investment bank and institutional broker-dealer based in New York. He has over 6 years of experience as a life sciences analyst writing research on publicly traded equities. Prior to MLV, he was an equity analyst with Westport Capital Markets and Cantor Fitzgerald. Prior to working as an analyst, Dr Zavoico established his own consulting company serving the biotech and pharmaceutical industries by providing competitive intelligence and marketing research, due diligence services, and guidance in regulatory affairs. He also wrote extensively on healthcare and the biotech and pharmaceutical industries for periodicals targeting the general public and industry executives. Dr Zavoico began his career as a Senior Research Scientist at Bristol-Myers Squibb Co., moving on to management positions at Alexion Pharmaceuticals, Inc. and T Cell Sciences, Inc. (now Celldex Therapeutics, Inc.). He has a BS in Biology from St. Lawrence University and PhD in Physiology from the University of Virginia and has held post-doctoral positions at the University of Connecticut Health Sciences Center and Brigham and Women’s Hospital and Harvard Medical School.

Jennifer Henry, PhD

The New York Academy of Sciences

Speakers

Jonathan N. Barasch, MD, PhD

Columbia University Medical Center

Jonathan Barasch MD PhD studied organic and biochemistry at Dartmouth College and then completed medical and graduate studies at Columbia where he is an Associate Professor of Medicine and Cell Biology. He studies growth factors in the embryonic and adult kidney focusing on iron transport.

Colin Meyer, MD

Reata Pharmaceuticals, Inc.

Dr. Meyer is the Vice President, Product Development of Reata Pharmaceuticals and joined the company as its second employee. Dr. Meyer's primary role is to develop and implement strategies to move product candidates expeditiously through all stages of development. His duties include overseeing preclinical development, clinical pharmacology, and working with Reata's senior leadership team to design and implement development strategies for drug candidates. Dr. Meyer received a B.S. in chemistry with specialization in biochemistry and a B.A. in biology from the University of Virginia. He received an M.D. from the University of Texas Southwestern Medical School and an M.B.A. from Southern Methodist University Cox School of Business.

Nick Vaziri, MD

University of California, Irvine

Dr. Vaziri, MD, is emeritus professor of medicine, physiology and biophysics at the University of California, Schools of Medicine and Biological Science, Irvine, California. He is former chair of the Department of Medicine and past president of the School of Medicine’s academic senate at the University of California Irvine. He is a Master and a Laureate of the American College of Physicians, past president of the Western Association of Physicians, past president of the American Paraplegia Society, and recipient of numerous prestigious awards. He serves on the editorial board of several scientific journals.

Dr Vaziri has authored close to 500 original papers and 150 invited book chapters, reviews, and editorials. He has made seminal contributions to the understanding of the molecular mechanisms of lipid disorders, oxidative stress and inflammation in chronic renal disease.

David Warnock, MD

University of Alabama at Birmingham

Dr. Warnock's focus is on the factors, genetic and environmental that contribute to hypertension and chronic kidney disease. The spectrum extends from basic studies of salt and water transport systems to population based studies of the prevalence of CKD and the association with stroke and heart disease. Another focus is inherited disorders of renal function, with a current emphasis on the renal manifestations of Fabry disease. Over 40 patients with Fabry disease have been identified in Alabama and approximately 20 of them have been started on Enzyme Replacement Therapy.

A major part of current nephrology practice is focused on management of kidney disease in adults with type 2 diabetes mellitus, the most common cause of end-stage renal disease in many parts of the world. Dr. Warnock participated as an investigator in the phase 2B studies of bardoxolone methy in the treatment of moderate to severe chronic kidney disease in type 2 diabetics (N Engl J Med 365: 327-336, 2011), and now serves as a Senior Medial Advisor to Reata Pharma in Irving, Texas as bardoxolone methyl moves forward into the phase 3 outcome study (BEACON Trial) in partnership with Abbott Pharmaceuticals.

David Gene Warnock was born in Parker, Arizona on March 5, 1945. He received a BA degree in 1966 from the University of California at Berkeley and received his MD degree in 1970 from the University of California, San Francisco. His clinical training was completed at the University of California, San Francisco, including a 1 year research fellowship with Isidore Edelman, MD in the Cardiovascular Research Institute. Following a fellowship with Maurice Burg, MD at the NIH, Dr. Warnock returned to UCSF as a faculty member. He served as the Section Chief at the San Francisco VA Medical Center during the last 5 years of his appointment at UCSF. Following a sabbatical with Bernard Rossier, MD at the Institute of Pharmacology in Lausanne, Switzerland, Dr. Warnock was recruited to UAB, and served as the Director of Nephrology from 1988 to 2008. Dr. Warnock served at the Director of the Office of Human Research at UAB from May 1, 2005 through September 30, 2008. He spent a 6-month sabbatical in 2008 at the College de France in Paris with Frederic Jaisser and Pierre Corvol. Dr. Warnock’s research interests include acid-base physiology, sodium transport mechanisms, chronic kidney disease, diabetes and kidney disease, and inherited renal diseases.